← SynDRA
CAPECITABINE
SynDRA canonical compound SYN0020552 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TYMS |
|---|
| Mechanism of action | Thymidylate synthase inhibitor |
|---|
| Indication | breast cancer | colorectal cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- DNA synthesis inhibitor
- thymidylate synthase inhibitor
- TYMS INHIBITOR
- Inhibitor
Drug classes
- Nucleic Acid Synthesis Inhibitors
- Nucleoside Metabolic Inhibitor
- Antimetabolites
- Antimetabolites, Antineoplastic
- Antineoplastic Agents
- Noxae
ATC classes
Cross-references
Synonyms
- capecitibine
- capecytabine
- capiibine
- captabin
- xeloda
- Capecitabina
- Capecitabine accord
- Capecitabine medac
- Capecitabine sun
- Capecitabine teva
- Capecitibine
- Capecytabine
- Capiibine
- Captabin
- Ecansya
- NSC-759853
- RO 09-1978/000
- RO-09-1978000
- RO-091978000
- Ro-09-1978-000
- Capecitabine component of xeliri capecitibine
- Capecitabine component of xelox
- Ecansya (previously capecitabine krka)
- Xeloda
- Capecitabin
- Capecitabinum
- Caxeta
- Xabine
- Capecitabine [USAN]
- R340;R-340
- RG-340
- Ro-09-1978
- Xeloda (TN)
- Ro-09-1978/000
- Xeloda, Captabin, Capecitabine
- Capecitabine (JAN/USAN/INN)
- N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
- Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Reported adverse events
- Alopecia
- Arthralgia
- Asthenia
- Constipation
- Cough
- Dermatitis
- Dizziness
- Dyspepsia
- Fatigue
- Headache
- Infection
- Lethargy
Look up CAPECITABINE in the interactive SynDRA portal →